16/09/2026 Daiichi Sankyo Secures Japan Approvals for Enhertu and Datroway in First-Line Breast Cancer OncoC4 Receives US FDA Fast Track Designation for Cesalatamig in NSCLC Daiichi Sankyo Secures Japan Approvals for Enhertu and Datroway in First-Line Breast Cancer (Ref) Daiichi Sankyo announced the approval of two antibody-drug conjugates in Japan, expanding their use into the first-line metastatic breast cancer setting The approvals include Enhertu (trastuzumab deruxtecan)

15/09/2026 Ivonescimab significantly prolonged OS vs pembrolizumab in 1L PD-L1+ NSCLC in Chinese patients US FDA Fast Track Designation Granted for KST-6051 in Advanced Solid Tumors US FDA Accepts NDA for Bezuclastinib in Advanced Systemic Mastocytosis CSPC's EGFR ADC SYS6010 Receives NMPA Breakthrough Therapy Designation in NSCLC US FDA Accepts NDA for Bezuclastinib in Advanced Systemic Mastocytosis CSPC's EGFR ADC SYS6010 Receives NMPA Breakthrough Therapy Designation in NS